Ratings Medacta Group SA

Equities

MOVE

CH0468525222

Real-time Estimate Cboe Europe Other stock markets 09:32:44 2023-12-06 am EST			5-day change	1st Jan Change
111.8 ^CHF	-1.06%		-4.94%	+8.35%

Nov. 30	Medacta to Expand Swiss Facilities to Boost Production Capacity	MT
Oct. 30	Medacta Group to Launch Optimized Knee Implant	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

With an expected P/E ratio at 33.82 and 27.42 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
With an enterprise value anticipated at 4.59 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
MEDACTA GROUP SA	+8.35%	2 577 M $	B
ABBOTT LABORATORIES	-4.95%	181 B $	C+
MEDTRONIC PLC	+1.42%	105 B $	C
BECTON, DICKINSON AND COMPANY	-8.14%	67 437 M $	A
DEXCOM, INC.	+3.50%	45 283 M $	B-
CENCORA CORPORATION	+22.94%	40 545 M $	B-
HOYA CORPORATION	+30.89%	38 230 M $	B+
WEST PHARMACEUTICAL SERVICES, INC.	+45.94%	25 413 M $	A-
ZIMMER BIOMET HOLDINGS, INC.	-9.16%	24 204 M $	B
TERUMO CORPORATION	+27.18%	23 483 M $	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes